Kornimate/medical-research-clean huggingface dataset:
efficacy of minoxidil in children with williams-beuren syndrome

Conditions: Williams Beuren Syndrome

Summary: the williams-beuren syndrome (wbs) is a sporadic congenital disorder characterized by a multisystem developmental impairment. this syndrome is caused by a microdeletion in chromosome 7q11.23 that encompasses loss of the elastin locus. elastin, which is part of the extracellular matrix, controls proliferation of vascular smooth muscle cells (vsmcs) and stabilizes arterial structure. loss of elastin gene in wbs patients has been claimed to provide a biological basis for the abnormal elastic fibre properties leading to cardiovascular abnormalities like supravalvular aortic stenosis (svas), hypertension, arteriosclerosis and stenosis in more than 50% of wbs children. these cardiovascular pathologies result in important consequences and neither curative nor preventive medicinal treatments exist at this time. surgery is needed in more than half cases, while it is often leading to complications. minoxidil is a well-known antihypertensive drug used in adults and children. furthermore, according to animal studies, minoxidil seems to increase arterial elastin content by decreasing elastase activity in these tissues. other data demonstrate that minoxidil specifically stimulate elastin synthesis. working hypothesis:if insufficient elastin synthesis leads to vascular complications and arterial hypertension in children with wbs, restoration of sufficient quantity of elastin should then result in prevention or inhibition of vascular malformations and improvement in arterial tension. therefore, as a pharmacological agent capable to stimulate elastin expression, minoxidil might be a useful drug for the treatment of abnormal elastin metabolism in wbs children. objective:to evaluate the efficacy of minoxidil on cardiovascular structure in children with williams beuren syndrome. methodology: randomized controlled trial on two parallel group (23 patients in each arm) main criterion:variation of carotid intima-media thickness (imt) before and after 12 months of treatment with minoxidil versus placebo secondary intermediate criteria of the vascular properties are arterial stiffness, cardiac and renal stenosis, arterial tension. total study duration:30 months including a 12 month-recruitment period


Eligibility criteria:
inclusion criteria: * proven diagnosis of williams beuren syndrome (genetic test) * normotension or hypertension, treated or not * male or female, * 6\< age \<18, * negative pregnancy test for childbearing potential female * effective birth control for sexually active female * signed consent form collected from parents or legal guardian exclusion criteria: * pulmonary hypertension secondary to mitral stenosis * myocardial infarction within 1 month prior randomization * known allergies to minoxidil or any of the components of lonoten. * asthma * renal failure (creatinine clearance \<40ml/min) * no affiliation to a national health insurance program (social security) * intolerance to lactose * current vasodilator anti hypertensive treatment

Keywords: williams beuren syndrome cardiovascular abnormalities cardiovascular structure
efficacy and safety of tacrolimus in combination with ripertamab in the initial treatment of patients with mcd

Conditions: Minimal Change Disease

Summary: to evaluate the safety and efficacy of ripertamab and its combination with tacrolimus in the initial treatment of mcd to provide a treatment regimen with higher remission rates, lower recurrence rates, and fewer side effects in patients with mcd.

minimal change disease is the third most common primary kidney disease in adults with idiopathic nephrotic syndrome. the pathological features of the disease are no or only slight changes under light microscope, and the foot process fusion under electron microscope. the kdigo guidelines recommend oral adequate doses of glucocorticoids as the initial treatment for adults with mcd. however, 48%-76% of patients relapse after tapering or gradual discontinuation of the drug, requiring a high cumulative dose of glucocorticoids. as the cumulative dose of glucocorticoids increases, the potential for side effects increases. in addition, 10% to 30% of patients frequently relapse, and 15% to 30% of these are steroid dependent. therefore, the clinical goals for patients with mcd are to achieve early remission of proteinuria, reduce hormonal side effects, and more importantly, prevent the recurrence of proteinuria.

Eligibility criteria:
inclusion criteria: 1. age 18-80 years old; 2. primary minimal change disease confirmed by renal biopsy (initial therapy); 3. 24h-utp\>3.5g/d or pcr\>3500mg/g, and serum albumin\<30g/l; 4. agree to participate in the project and sign the informed consent. exclusion criteria: 1. secondary minimal change disease; 2. egfr\<60 ml/min/1.73m2; 3. had history of mental disease, dysnoesia, serious cardiovascular and cerebrovascular diseases, pulmonary insufficiency, malignant tumors or other major diseases that are not suitable for clinical experiments; 4. active bleeding in the gastrointestinal tract; 5. prior treatment with corticosteroids or other immunosuppressants; 6. hbv, hcv, hiv or other untreated infections, congenital or acquired immunodeficiency diseases; 7. have been vaccinated with live vaccine in the past four weeks; 8. serum bilirubin \> 3.6mg/dl for at least 1 month or liver function ≥3 times the upper limit of normal value; 9. allergic to prednisolone, tacrolimus, or ripertamab; 10. reluctance to use contraception or plan pregnancy/lactation within 6 months of study completion; 11. had history of alcohol/drug abuse; 12. unable to give informed consent.
study of the correlation between specific genes and cognitive dysfunction after surgery

Conditions: Genotype; Cognitive Impairment

Summary: the purpose of this study is to determine whether a certain clock-gene (hper3) with the 5/5 genotype carries a higher risk of post-operative cognitive dysfunction.


Eligibility criteria:
inclusion criteria: * patients undergoing non-cardiac and non-neurological surgery in either regional or general anesthesia exclusion criteria: * daily use of major tranquilizers or antipsychotic medication * known disease of the cns * score less than 24/30 points in mmse

Keywords: pocd clock-gene genotypes hper3
robotic assisted balance and exoskeleton training (reaction) in neurorehabilitation: a feasibility study

Conditions: Stroke; Spinal Cord Injury

Summary: the goal of this clinical trial is to explore the effect on walking speed of a new robotic assisted balance and gait trainer (reaction) and their subsystems in individuals with neurological disorders. the study will provide insight in the feasibility of reaction. participants will: * participate in two sessions in which every session contains a walking task and balance tasks * end the study with a semi-structured interview

the first day will be focusing on 4 conditions: tasks without aid, tasks with regular aid, task with the able regain and tasks with reaction. the first and third condition consist of a walking task and balance tasks, the second and fourth condition is only focusing on the walking task with the aim of getting familiar to the device and the walking task. the second day will also be focusing on four conditions: tasks without aid, tasks with aid, tasks with the gable core and task with reaction (fig 3.2). the conditions 'tasks without aid', 'tasks with the gable core' and 'tasks with reaction' consist of a walking task and balance tasks (similar to day 1). the condition 'tasks with aid' only consists of a walking task. a semi-structured interview with the corresponding physiotherapist and patient will be held to gather more information about usability and feasibility of reaction from a therapist's and patient's perspective.

Eligibility criteria:
in order to be eligible to participate in this study, a participant must meet all of the following criteria: * age \> 16 years * able to give informed consent stroke patients: * first-ever ischemic or haemorrhagic stroke * fac score between 3 and 4 * (sub)acute or chronic phase sci patients: * neurological injury levels ranging from c5 to t9 * motor incomplete spinal cord injury (asia impairment score of c or d) * able to walk independently (without physical support) exclusion criteria: a potential participant who meets any of the following criteria will be excluded from participation in this study: * premorbid disability of lower extremity * progressive neurological diseases like dementia or parkinson * skin lesions or severely impaired sensation at the hemiparetic leg * contraindication for mobilization, like lower limb fracture * insufficient knowledge of the dutch language to understand the purpose or meth-ods of the study * pregnancy

Keywords: exoskeleton gait trainer neurological disease rehabilitation
bnp (nesiritide) vs. placebo to protect kidney function in patients undergoing heart bypass surgery.

Conditions: Acute Kidney Failure

Summary: use of bnp (nesiritide) vs placebo to help protect kidney function in patients undergoing heart bypass surgery.

this is a randomized, double-blind, placebo controlled study of low dose nesiritide to prevent renal insufficiency after cardiopulmonary bypass surgery. patients included are those with greater than mild renal insufficiency preoperatively as defined by having a creatinine clearance of less than 50 ml/minute determined by the cockroft-gault formula. the infusion of nesiritide (bnp) 0.005 mcg/kg/minute or placebo begins 1 hour before surgery and runs for 24 hours started after the induction of anesthesia prior to cardiopulmonary bypass.

Eligibility criteria:
inclusion criteria: * patients \> 18 years old, undergoing cardiac surgery requiring cardiopulmonary bypass with baseline creatinine clearance \< 50 ml/min and who are not dialysis dependent. exclusion criteria: * cardiogenic shock or hypotension with systolic bp \< 90 mmhg. * patients with acute or chronic aortic dissection. * patients who are enrolled in other studies that have an effect the renal function.
transcranial direct current stimulation and the interaction between chronic pain and the intestinal epithelial barrier in patients with chronic inflammatory bowel diseases (ibd)

Conditions: Inflammatory Bowel Diseases

Summary: in the study the investigators aim to test whether transcranial direct current stimulation (tdcs) induced pain reduction is in association with functional changes in the brain measured with magnetic resonance imaging (mri) and also with a change in permeability of the intestinal epithelial barrier in patients with chronic inflammatory bowel diseases (ibd) hypothesis: transcranial direct current stimulation can reduce the perception of pain in patients with chronic inflammatory bowel diseases, which is in association with changes in the brain measured via mri. additionally, transcranial direct current stimulation and the induced pain reduction influence the permeability of the intestinal epithelial barrier


Eligibility criteria:
inclusion criteria: * inflammatory bowel disease * chronic pain (more than 3 months) * pain (vas \> 3/10) exclusion criteria: * contraindication to transcranial direct current stimulation * contraindications to functional magnetic resonance imaging (fmri) * pregnancy * sever internal or psychiatric condition
safety and immunogenicity of a/h1n1-soiv (swine flu) vaccine with and without adjuvant in children, adolescents and adults (3 to 64 years)

Conditions: Novel 2009 Influenza H1N1

Summary: this study will evaluate the safety and immunogenicity of different combinations of a/h1n1 s-oiv (swine flu) vaccine in healthy young children, adolescents, and adults.


Eligibility criteria:
inclusion criteria: * children, adolescents, and adults 3 to 64 years of age in good health as determined by medical history, physical assessment and clinical judgement of the investigator and without influenza within the past 6 months. exclusion criteria: * history of serious disease. * history of serious reaction following administration of vaccine or hypersensitivity to vaccine components. * known or suspected impairment/alteration of immune function. * receipt or planned receipt of seasonal trivalent influenza vaccine within 1 week before or after each study vaccination. for additional entry criteria, please refer to protocol.

Keywords: swine flu flu vaccine adjuvant
digital youth-nominated support team (yst) program

Conditions: Suicide

Summary: the electronic youth-nominated support team (eyst), is experimental. the purpose of this study is to get feedback from users about eyst. another purpose of this study is to learn how well eyst helps youth.

assessment data from multiple stakeholders (i.e., youth, parents, and support adults) will be collected at baseline, 4 weeks, 8 weeks, and 12 weeks via self-report and semi-structured interviews.

Eligibility criteria:
inclusion criteria: 1. inpatient psychiatric patients who have attempted suicide or have documented suicide ideation (si) and a plan to harm themselves at admission. 2. understand written and spoken english. 3. own a smartphone or mobile phone. 4. willing and able to complete enrollment procedures. 5. parent or guardian and youth able to understand the nature of the study and provide written informed consent and assent for youth 6. patients who are able to provide at least one verifiable contact for emergency or tracking purposes. exclusion criteria: 1. patients with active psychosis. 2. patients experiencing substance withdrawal. 3. currently enrolled in other treatment studies for the symptoms and behaviors targeted. 4. patient unwilling or unable to wear a mask during in person study procedures, if mandated due to current covid/health safety guidelines. 5. patients who in the judgment of the investigator would have an unfavorable risk or benefit profile with respect to eyst. 6. any other psychiatric or medical condition or custody arrangement that in the investigators' opinion would preclude informed consent or assent or participation in the trial.

Keywords: social network website
ventilator weaning outcome between niv-nava and nasal cpap (or imv ) modes in premature neonates

Conditions: Respiratory Distress Syndrome in Premature Infant

Summary: premature neonates are prone to respiratory distress and need ventilator support because of the rapid breathing and large variations in respiratory patterns. the setting and adjustment of the ventilator for premature neonate is not easy, often resulting in poor patient-ventilator interaction, increased work of breathing, patient discomfort and delayed weaning . recently, a new ventilation mode (nava; neurally adjusted ventilatory assist) mode, allows the respirator to provide a proportional ventilation mode based on the patients' diaphragm electrical activity, which was validated in many domestic and international clinical researches. the nava mode improves patient-ventilator interaction, reduces work of breathing and contributes to early weaning and extubation . when participating in this study, the neonate with receive a special oral tube placement, which is used to replace the original gastric tube to monitor the electrical activity of the diaphragm.

premature neonates are prone to respiratory distress and need ventilator support because of the rapid breathing and large variations in respiratory patterns. the setting and adjustment of the ventilator for premature neonate is not easy, often resulting in poor patient-ventilator interaction, increased work of breathing, patient discomfort and delayed weaning . recently, a new ventilation mode (nava; neurally adjusted ventilatory assist) mode, allows the respirator to provide a proportional ventilation mode based on the patients' diaphragm electrical activity, which was validated in many domestic and international clinical researches. the nava mode improves patient-ventilator interaction, reduces work of breathing and contributes to early weaning and extubation . when participating in this study, the neonate with receive a special oral tube placement, which is used to replace the original gastric tube to monitor the electrical activity of the diaphragm. the aims of the study are: 1. to select the appropriate ventilation mode and parameters (for example, switch to niv-nava mode); 2. to monitor intermittent apnea, bradycardia and the frequency of cyanosis, 3. to pay attention to the changes in maximum peak pressure, adjust appropriate pressure support, and avoid lung injury. the predicted outcomes of nava mode for premature neonate may include : 1. measurement of the lower pip value to maintain proper and synchronized ventilation; 2. monitoring of the diaphragm activity (edi) signal to evaluate the work of breathing and estimate the weaning time.

Eligibility criteria:
inclusion criteria: 1. premature \>30week 2. respiratory distress exclusion criteria: 1. premature \< 30weeks 2. ent contraindication: fistula 3. contraindication with orogastric tube or nasogastric
adherence of stalevo, entacapone and levodopa

Conditions: Parkinson's Disease

Summary: to test if combining two antiparkinson drugs into a single tablet improves accuracy of medicine intake by the patient. to test if patients with parkinson's disease who take medicines at regular time intervals have smoother symptom control.


Eligibility criteria:
inclusion criteria: * patients diagnosed with parkinson's disease aged between 18 and 85 years fulfilling uk brain bank criteria. * current levodopa therapy prescribed on a regular basis three or more times per day but requiring entacapone because of 'wearing off' * able to manipulate electronic monitoring bottles and complete questionnaires exclusion criteria: * current use of compliance aid such that study participation would be detrimental to patient's adherence * pregnancy or breast feeding * excess alcohol (over 21 units per week for women and 28 units for men) * mini mental state examination of less than 26. * severe depression (geriatric depression score over 20)
safety of serum for post-inflammatory on hyperpigmentation skin

Conditions: Healthy

Summary: this study aims to investigate the safety of serum product containing low dose of alpha hydroxy acid (aha) i.e. 1% glycolic acid and lactic acid and polyglutamate acid derivatives (pga) for post-inflammatory hyperpigmentation skin in malaysia. the study duration is 8 weeks and the skin assessment will be carried out at baseline, week 4 and week 8.the main questions this study aims to answer are: 1. to investigate the safety of serum containing low concentration aha (1% glycolic acid and lactic acid) and pga for post-inflammatory hyperpigmentation skin among malaysian. 2. to assess the patient satisfaction after using serum containing low concentration aha (1% glycolic acid and lactic acid) and pga among malaysian.


Eligibility criteria:
inclusion criteria: * malaysian from 18 to 40 years old. * participants with post-inflammatory hyperpigmentation (pih). exclusion criteria: * participant with known systemic or skin disease and any underlying medical illness * pregnant, breastfeeding women or planned pregnancy during the study period. * had reported history of dermatologic conditions (i.e. atopic dermatitis, psoriasis) or known allergies to any ingredients that may be found in the product. * had any cosmetic procedures such as botox, laser and light treatment, facial surgery, chemical peel and any procedures that may improve skin texture 1 month before the study. * had history of taking isotretinoin for the past 6 or 12 month and aha (alpha hydroxyl acids) containing products or any other products for treating hyperpigmentation skin or melasma 1 month prior to study.

Keywords: aesthetic cosmetic post-inflammatory hyperpigmentation (pih)
supporting oral self-care of patients with periodontitis through motivational interview

Conditions: Periodontal Diseases; Patient Education; Self-Care

Summary: the aim of this study was to evaluate the potential additive effect of motivational interviewing (mi) on gingival health and self-care. our hypothesis was that the motivational interviewing would result in improved gingival health and self-care compared to prevailing patient education.

the study is designed as a randomized, double-blinded, controlled clinical trial of 6-month duration involving patients with diagnosed periodontitis. the subjects are randomized to intervention or control group using the randomizing list. for both groups, necessary non-surgical periodontal treatments will be done. in the intervention group the mi-intervention is used as a part of normal dental hygienist appointment and if patient need more than one visit, mi was used in every visit. in control group prevailing, more professional-centered education is used. dental hygienist define patients educational needs and give direct instructions how to change behaviour and self-care.

Eligibility criteria:
inclusion criteria: * adults, over 18-year-old * cpi (community periodontal index) 3 in at least two sextants and * diagnosed parodontitis * the previous treatment period should have been more than one year ago. exclusion criteria: * pregnancy (or the planning of pregnancy) * immunosuppressive illness or a medication, * hepatitis, hiv, mrsa (methicillin-resistant staphylococcus aureus) * a bleeding illness or a anticoagulant (excluding primalan 100-200 mg / a day) * the labile diabetes * cytotoxic treatment * a need for the antibiotic prophylaxis.
a study to evaluate a study drug, dcb-bo1202, for alleviating liver fibrosis in liver cancer patients

Conditions: Liver Fibrosis; HEPATITIS B CHRONIC; Hepatocellular Carcinoma

Summary: the purpose of this study is to determine whether an investigational drug dcb-bo1202 is effective and safe in the treatment of liver fibrosis in hbv patients having experienced intermediate stage hepatocellular carcinoma (hcc)

the study will include the first 188 subjects who are randomized. the purpose of study is to collect efficacy results to evaluate treatment effect on the primary endpoint. the second endpoints is to evaluate drug safety on the incidence of the primary endpoint through the treatment period.

Eligibility criteria:
inclusion criteria: 1. aged 20-65 years (inclusive) of either gender 2. with evidence of hbv infection confirmed by positive for hepatitis b virus antigen (hbsag) 3. with barcelona clinic liver cancer (bclc) intermediate stage (bclc-b) hepatocellular carcinoma (hcc) 4. having received radiofrequency ablation (rfa) or transarterial embolization (tae) for hepatitis b virus (hbv) related hepatocellular carcinoma at least 4 weeks before screening 5. with liver stiffness measurement (assessed by fibroscan®) of 7-20 kpa 6. able to understand and willing to sign the informed consent exclusion criteria: 1. evidence or history of chronic hepatitis caused by hepatitis c virus (hcv) 2. with abnormal organ functions such as absolute neutrophil count (anc) \ 2 mg/dl, alanine aminotransferase (ast) or alt \> 5 x upper normal limit of the current institution; bilirubin \> 2.5 mg/dl, prothrombin time (pt) prolongation \> 4 sec above upper limit of normal 3. with uncontrolled infection or serious infection within the past 4 weeks 4. with any other carcinoma except skin cancer 5. women who are pregnant or breast-feeding or with child-bearing potential but unable or unwilling to practice a highly effective means of contraception 6. active substance abuse, including alcohol, which, in the opinion of the investigator, risks impairing the ability of the patient to comply with the protocol 7. history of allergy to any substance of investigational products 8. with known human immunodeficiency virus (hiv) infection 9. judged to be not applicable to this study by investigator such as difficulty of follow-up observation 10. with any other serious diseases/medical history considered by the investigator not in the condition to enter the trial 11. administered with any anti-hbv drugs within 4 weeks of entering this study. (note: anti-hbv treatments are allowed to be taken during study period when necessary.) 12. having participated other investigational study within 4 weeks of entering this study